JP2015521626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521626A5 JP2015521626A5 JP2015518626A JP2015518626A JP2015521626A5 JP 2015521626 A5 JP2015521626 A5 JP 2015521626A5 JP 2015518626 A JP2015518626 A JP 2015518626A JP 2015518626 A JP2015518626 A JP 2015518626A JP 2015521626 A5 JP2015521626 A5 JP 2015521626A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- oligonucleotide
- administration
- pharmaceutical composition
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 108091070501 miRNA Proteins 0.000 claims description 20
- 239000002679 microRNA Substances 0.000 claims description 16
- -1 miR-195 Proteins 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 210000005003 heart tissue Anatomy 0.000 claims description 5
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 108091007775 MIR1-1 Proteins 0.000 claims description 2
- 108091026807 MiR-214 Proteins 0.000 claims description 2
- 108091081013 MiR-33 Proteins 0.000 claims description 2
- 108091028066 Mir-126 Proteins 0.000 claims description 2
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 claims description 2
- 108091027766 Mir-143 Proteins 0.000 claims description 2
- 108091028684 Mir-145 Proteins 0.000 claims description 2
- 108091060302 Mir-320 Proteins 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 238000001246 colloidal dispersion Methods 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 108091053410 let-7 family Proteins 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 2
- 108091044592 miR-1-1 stem-loop Proteins 0.000 claims description 2
- 108091045542 miR-1-2 stem-loop Proteins 0.000 claims description 2
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 2
- 108091023685 miR-133 stem-loop Proteins 0.000 claims description 2
- 108091031326 miR-15b stem-loop Proteins 0.000 claims description 2
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 2
- 108091074057 miR-16-1 stem-loop Proteins 0.000 claims description 2
- 108091056204 miR-16-2 stem-loop Proteins 0.000 claims description 2
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 2
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 2
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 2
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 2
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 2
- 108091080321 miR-222 stem-loop Proteins 0.000 claims description 2
- 108091092825 miR-24 stem-loop Proteins 0.000 claims description 2
- 108091032978 miR-24-3 stem-loop Proteins 0.000 claims description 2
- 108091064025 miR-24-4 stem-loop Proteins 0.000 claims description 2
- 108091085564 miR-25 stem-loop Proteins 0.000 claims description 2
- 108091080167 miR-25-1 stem-loop Proteins 0.000 claims description 2
- 108091083056 miR-25-2 stem-loop Proteins 0.000 claims description 2
- 108091061970 miR-26a stem-loop Proteins 0.000 claims description 2
- 108091007431 miR-29 Proteins 0.000 claims description 2
- 108091029119 miR-34a stem-loop Proteins 0.000 claims description 2
- 108091079013 miR-34b Proteins 0.000 claims description 2
- 108091084018 miR-34b stem-loop Proteins 0.000 claims description 2
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 claims description 2
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 claims description 2
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 claims description 2
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 claims description 2
- 108091090583 miR-34c stem-loop Proteins 0.000 claims description 2
- 108091082133 miR-34c-1 stem-loop Proteins 0.000 claims description 2
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims description 2
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims description 2
- 108091030938 miR-424 stem-loop Proteins 0.000 claims description 2
- 108091052738 miR-486-1 stem-loop Proteins 0.000 claims description 2
- 108091030654 miR-486-2 stem-loop Proteins 0.000 claims description 2
- 108091063340 miR-497 stem-loop Proteins 0.000 claims description 2
- 108091034121 miR-92a stem-loop Proteins 0.000 claims description 2
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108091071651 miR-208 stem-loop Proteins 0.000 description 1
- 108091084446 miR-208a stem-loop Proteins 0.000 description 1
- 108091062547 miR-208a-1 stem-loop Proteins 0.000 description 1
- 108091055375 miR-208a-2 stem-loop Proteins 0.000 description 1
- 108091047268 miR-208b stem-loop Proteins 0.000 description 1
- 108091056170 miR-499 stem-loop Proteins 0.000 description 1
- 108091050885 miR-499-1 stem-loop Proteins 0.000 description 1
- 108091038523 miR-499-2 stem-loop Proteins 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662746P | 2012-06-21 | 2012-06-21 | |
| US61/662,746 | 2012-06-21 | ||
| US201361801533P | 2013-03-15 | 2013-03-15 | |
| US61/801,533 | 2013-03-15 | ||
| PCT/US2013/047157 WO2013192576A2 (en) | 2012-06-21 | 2013-06-21 | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017171211A Division JP2017217007A (ja) | 2012-06-21 | 2017-09-06 | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521626A JP2015521626A (ja) | 2015-07-30 |
| JP2015521626A5 true JP2015521626A5 (cg-RX-API-DMAC7.html) | 2016-07-28 |
| JP6208228B2 JP6208228B2 (ja) | 2017-10-04 |
Family
ID=49769732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518626A Expired - Fee Related JP6208228B2 (ja) | 2012-06-21 | 2013-06-21 | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
| JP2017171211A Pending JP2017217007A (ja) | 2012-06-21 | 2017-09-06 | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017171211A Pending JP2017217007A (ja) | 2012-06-21 | 2017-09-06 | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9388408B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2864482A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6208228B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101928418B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107236735B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013278011B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2876180C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3354734T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2801875T3 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1209781A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX355408B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013192576A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083005A2 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| PL2702155T3 (pl) | 2011-04-25 | 2017-09-29 | Regulus Therapeutics Inc. | Związki mikroRNA i sposoby modulowania aktywności miR-21 |
| IN2014DN09134A (cg-RX-API-DMAC7.html) | 2012-04-25 | 2015-05-22 | Regulus Therapeutics Inc | |
| CN107236735B (zh) | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| EP2757157A1 (en) * | 2013-01-17 | 2014-07-23 | Ecole Polytechnique Federale de Lausanne (EPFL) | Modulation of mitophagy and use thereof |
| CA2902623A1 (en) | 2013-03-15 | 2014-09-25 | MiRagen Therapeutics, Inc. | Locked nucleic acid inhibitor of mir-145 and uses thereof |
| CN105378080A (zh) | 2013-05-01 | 2016-03-02 | 莱古路斯治疗法股份有限公司 | 用于调节mir-122的微小rna化合物和方法 |
| KR20170042625A (ko) | 2014-08-04 | 2017-04-19 | 미라젠 세러퓨틱스 인코포레이티드 | Myh7b의 억제제 및 이의 용도 |
| US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
| WO2016069717A1 (en) * | 2014-10-28 | 2016-05-06 | MiRagen Therapeutics, Inc. | Inhibitors of mirnas in regulation of arterial stiffness and uses thereof |
| BR112017015618A2 (pt) | 2015-01-20 | 2018-04-10 | Miragen Therapeutics Inc | inibidores de mir-92 e usos destes. |
| US10538769B2 (en) | 2015-09-04 | 2020-01-21 | Oregon State University | Renal selective inhibition of cytochrome P450 3A5 |
| US20180250325A1 (en) * | 2015-09-22 | 2018-09-06 | MiRagen Therapeutics, Inc. | Mir-19 modulators and uses thereof |
| US10801026B2 (en) * | 2015-10-15 | 2020-10-13 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
| EP3377073A4 (en) * | 2015-11-16 | 2019-06-26 | Ohio State Innovation Foundation | METHOD AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES WITH THE SURVIVAL MOTOR NEURON (SMN) PROTEIN |
| CN105435247A (zh) * | 2015-12-31 | 2016-03-30 | 中国医学科学院基础医学研究所 | miR-378在预防和/或治疗肥胖症中的用途 |
| EP3449001B1 (en) * | 2016-04-29 | 2021-12-08 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| CN106011140B (zh) * | 2016-06-06 | 2018-12-18 | 同济大学 | 反义microRNA-25及其应用 |
| WO2017214953A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用 |
| WO2017214952A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| WO2017219166A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 一种同时抑制双 miRNA 表达的慢病毒载体及其应用 |
| WO2017219165A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异敲低人 miRNA-29a 和 miR-140 表达的慢病毒载体及其应用 |
| US20200276220A1 (en) * | 2016-07-07 | 2020-09-03 | MiRagen Therapeutics, Inc. | Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors |
| US11266717B2 (en) | 2016-08-12 | 2022-03-08 | Immunowork, Llc | Diagnosis, prevention, and/or treatment of autoimmune diseases |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3601565A4 (en) * | 2017-03-25 | 2021-01-06 | Miragen Therapeutics, Inc. | MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE |
| CN110141577A (zh) * | 2018-02-13 | 2019-08-20 | 上海三炬生物科技有限公司 | miRNA-24-3p核苷酸类似物在制备药物中的应用 |
| KR20200132920A (ko) * | 2018-03-14 | 2020-11-25 | 베스 이스라엘 데코니스 메디칼 센터 | 마이크로-rna 및 비만 |
| WO2019217369A1 (en) | 2018-05-08 | 2019-11-14 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect |
| US20220056443A1 (en) * | 2018-09-06 | 2022-02-24 | Aptamir Therapeutics, Inc. | Metabolic benefits of short mir-22 mirna antagomir therapies |
| CN110358769A (zh) * | 2019-07-30 | 2019-10-22 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 经锁核酸和硫代磷酸修饰的miRNA类似物及其在制备抗肿瘤药物中的应用 |
| CN110433170B (zh) * | 2019-07-31 | 2021-04-27 | 南京医科大学 | 心脏抽吸液miR-28-5p在心脏疾病中的应用 |
| IT201900017234A1 (it) * | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA per il trattamento del leiomioma |
| US20220395587A1 (en) * | 2019-11-15 | 2022-12-15 | Duke University | Cellular molecular theranostics nanoprobe systems and methods |
| CN111118008B (zh) * | 2020-01-16 | 2023-08-22 | 南京医科大学 | Mcl1基因的3’-UTR序列及其应用 |
| US20230348913A1 (en) * | 2020-03-04 | 2023-11-02 | The Trustees Of Indiana University | Methods to re-engage a fetal wound healing pathway for adult skin repair |
| CN116438305A (zh) * | 2020-07-23 | 2023-07-14 | 法兰克福大学 | 用于治疗心力衰竭的miRNA的组合抑制 |
| US20240301407A1 (en) * | 2021-01-18 | 2024-09-12 | Regen Innopharm Inc. | Composition comprising mir 145 inhibitor as active ingredient for treatment of myocardial infarction |
| WO2024165603A1 (en) | 2023-02-07 | 2024-08-15 | Universitetet I Tromsø - Norges Arktiske Universitet | Pharmaceutical composition for use in treatment of venous thromboembolism |
| GB202305535D0 (en) | 2023-04-14 | 2023-05-31 | Imperial College Innovations Ltd | Oligonucleotide decoy |
| WO2025008641A2 (en) * | 2023-07-06 | 2025-01-09 | Imperial College Innovations Limited | Rna molecule |
| WO2025104709A1 (en) * | 2023-11-17 | 2025-05-22 | Biorchestra Co., Ltd. | Microrna-378a-3p antisense oligonucleotides and uses thereof |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| WO1995003843A1 (en) | 1993-07-30 | 1995-02-09 | The Regents Of The University Of California | Endocardial infusion catheter |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| HRP20000751A2 (en) | 1998-05-26 | 2001-12-31 | Icn Pharmaceuticals | Novel nucleosides having bicyclic sugar moiety |
| EP1161554B1 (en) | 1999-03-18 | 2011-03-09 | Exiqon A/S | Detection of mutations in genes by specific lna primers |
| WO2001025478A1 (en) | 1999-10-04 | 2001-04-12 | Exiqon A/S | A method of increasing the specificity of oxy-lna oligonucleotides |
| ATE325806T1 (de) | 2000-10-04 | 2006-06-15 | Santaris Pharma As | Verbesserte synthese von purin-blockierten nukleinsäure-analoga |
| CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| EP2298358A1 (en) | 2002-05-06 | 2011-03-23 | Alnylam Pharmaceuticals Inc. | Methods for delivery of nucleic acids |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| DK1569661T3 (da) | 2002-11-18 | 2010-01-11 | Santaris Pharma As | Antisense design |
| DK1606406T4 (da) | 2003-03-21 | 2013-12-16 | Santaris Pharma As | Short Interfering RNA (siRNA) Analogues |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| GB2442373B (en) | 2003-11-26 | 2008-10-22 | Univ Massachusetts | Sequence -specific inhibition of small rna function |
| US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005079397A2 (en) | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
| JP4819788B2 (ja) | 2004-02-26 | 2011-11-24 | オスプレイ メディカル インク． | 分離用心循環 |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| EP1771563A2 (en) | 2004-05-28 | 2007-04-11 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
| EP1838852A2 (en) * | 2004-11-12 | 2007-10-03 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| US9550990B2 (en) | 2004-12-10 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
| US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| CA2604807C (en) | 2005-04-19 | 2018-06-12 | Basf Plant Science Gmbh | Improved methods controlling gene expression |
| CN101287834B (zh) | 2005-05-27 | 2016-11-09 | 圣拉法埃莱医院有限公司 | 基因载体 |
| CN104027818A (zh) | 2005-12-12 | 2014-09-10 | 北卡罗来纳大学查珀尔希尔分校 | 调节肌细胞增殖和分化的microrna |
| EP1966390A1 (en) | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| EP2007889A2 (en) * | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| US8466117B2 (en) | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
| US8304397B2 (en) | 2006-08-01 | 2012-11-06 | Board Of Regents, The University Of Texas System | Identification of a micro-RNA that activates expression of β-myosin heavy chain |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| WO2008147430A2 (en) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| EP2097527B1 (en) | 2006-11-23 | 2018-08-01 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
| CN102604951A (zh) | 2006-12-14 | 2012-07-25 | 诺瓦提斯公司 | 治疗肌肉和心血管病症的组合物和方法 |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| US20090105174A1 (en) | 2007-04-20 | 2009-04-23 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| BRPI0814991A2 (pt) | 2007-07-31 | 2015-03-31 | Univ Texas | Micro-rnas que controlam a expressão de miosina e identidade de miofibra. |
| WO2009026574A2 (en) | 2007-08-23 | 2009-02-26 | Keren Pharmaceutical, Inc. | Immunogenic compositions and uses thereof |
| ES2419129T3 (es) | 2007-09-14 | 2013-08-19 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo |
| MX2010003299A (es) * | 2007-10-04 | 2010-04-14 | Santaris Pharma As | Oligonucleotidos muy cortos (micromirs). |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| CN101424640B (zh) | 2007-11-02 | 2012-07-25 | 江苏命码生物科技有限公司 | 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法 |
| NZ585209A (en) | 2007-11-09 | 2012-08-31 | Univ Texas | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
| EP2225002A4 (en) | 2007-12-31 | 2011-06-22 | Nanocor Therapeutics Inc | RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2009114681A2 (en) | 2008-03-13 | 2009-09-17 | Dharmacon, Inc. | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| WO2009151600A2 (en) | 2008-06-10 | 2009-12-17 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| EP2310505B1 (en) * | 2008-06-30 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antidote oligomers |
| CN101386848A (zh) | 2008-08-12 | 2009-03-18 | 南京大学 | 细胞微粒子所载微小核糖核酸及其制备研究方法和应用 |
| EP2346883B1 (en) | 2008-09-23 | 2016-03-23 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| KR20110128838A (ko) * | 2009-02-04 | 2011-11-30 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 심장 질환 치료에서 ｍｉｒ－208 및 ｍｉｒ－499의 이중 표적화 |
| WO2010122538A1 (en) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
| CA2761106C (en) | 2009-05-05 | 2019-01-15 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| AU2010258875A1 (en) | 2009-06-08 | 2012-01-19 | Miragen Therapeutics | Chemical modification motifs for miRNA inhibitors and mimetics |
| US9078914B2 (en) | 2009-09-10 | 2015-07-14 | Velin-Pharma A/S | Method for the preparation of micro-RNA and its therapeutic application |
| US9364495B2 (en) | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
| US8592151B2 (en) | 2009-11-17 | 2013-11-26 | Musc Foundation For Research Development | Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids |
| WO2011106442A1 (en) | 2010-02-24 | 2011-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Control of cardiac growth, differentiation and hypertrophy |
| EP2550360B1 (en) | 2010-03-24 | 2017-08-30 | Mirrx Therapeutics A/s | Bivalent antisense oligonucleotides |
| EP2559442B1 (en) | 2010-04-13 | 2017-12-06 | Jiangsu Mingma Biotech Co., Ltd | Method for regulating microrna content in organisms and uses thereof |
| EP2561091B1 (en) | 2010-04-20 | 2014-08-06 | Comprehensive Biomarker Center GmbH | Complex mirna sets as novel biomarkers for an acute coronary syndrome |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| WO2011154553A2 (en) | 2010-06-11 | 2011-12-15 | Cellartis Ab | Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
| ITMI20101089A1 (it) | 2010-06-16 | 2011-12-17 | Istituto Naz Di Genetica Molecolare Ingm | Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario |
| CA2804791C (en) | 2010-07-08 | 2019-07-30 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
| GB201012418D0 (en) * | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
| US20130137753A1 (en) | 2010-08-03 | 2013-05-30 | University Of South Alabama | Methods and compositions for the diagnosis and treatment of breast cancer |
| WO2012020308A2 (en) | 2010-08-13 | 2012-02-16 | The University Court Of The University Of Glasgow | Cellular and molecular therapies |
| EP2609198B8 (en) | 2010-08-24 | 2018-03-28 | Sirna Therapeutics, Inc. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
| WO2012037254A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| WO2012061810A1 (en) * | 2010-11-05 | 2012-05-10 | Miragen Therapeutics | Base modified oligonucleotides |
| WO2012083005A2 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| WO2012149646A1 (en) | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Mirna inhibitors and their uses |
| AU2013201303C1 (en) | 2011-10-06 | 2016-06-23 | MiRagen Therapeutics, Inc. | Control of whole body energy homeostasis by microRNA regulation |
| GB201117482D0 (en) | 2011-10-11 | 2011-11-23 | Univ Dundee | Targetiing of miRNA precursors |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| DK2768958T3 (da) | 2011-10-18 | 2019-09-16 | Dicerna Pharmaceuticals Inc | Kationiske aminlipider og anvendelser deraf |
| JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン，インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| EP2604690A1 (en) | 2011-12-15 | 2013-06-19 | Oncostamen S.r.l. | MicroRNAs and uses thereof |
| US20140356459A1 (en) | 2011-12-15 | 2014-12-04 | Oncostamen S.R.L. | Micrornas and uses thereof |
| FR2984358A1 (fr) | 2011-12-16 | 2013-06-21 | Genethon | Methodes pour le diagnostic de dystrophies musculaires |
| CN107236735B (zh) | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
| ES2606636T3 (es) | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
| BR112017015618A2 (pt) | 2015-01-20 | 2018-04-10 | Miragen Therapeutics Inc | inibidores de mir-92 e usos destes. |
-
2013
- 2013-06-21 CN CN201710249089.9A patent/CN107236735B/zh not_active Expired - Fee Related
- 2013-06-21 HK HK15110337.4A patent/HK1209781A1/xx unknown
- 2013-06-21 MX MX2014015643A patent/MX355408B/es active IP Right Grant
- 2013-06-21 EP EP13807536.1A patent/EP2864482A4/en not_active Withdrawn
- 2013-06-21 AU AU2013278011A patent/AU2013278011B2/en not_active Ceased
- 2013-06-21 DK DK18154472.7T patent/DK3354734T3/da active
- 2013-06-21 KR KR1020157000512A patent/KR101928418B1/ko not_active Expired - Fee Related
- 2013-06-21 JP JP2015518626A patent/JP6208228B2/ja not_active Expired - Fee Related
- 2013-06-21 CA CA2876180A patent/CA2876180C/en not_active Expired - Fee Related
- 2013-06-21 ES ES18154472T patent/ES2801875T3/es active Active
- 2013-06-21 US US13/924,340 patent/US9388408B2/en not_active Expired - Fee Related
- 2013-06-21 EP EP18154472.7A patent/EP3354734B1/en active Active
- 2013-06-21 CN CN201380038840.0A patent/CN104685056A/zh active Pending
- 2013-06-21 WO PCT/US2013/047157 patent/WO2013192576A2/en not_active Ceased
-
2016
- 2016-05-13 US US15/154,711 patent/US9803202B2/en not_active Expired - Fee Related
-
2017
- 2017-09-06 JP JP2017171211A patent/JP2017217007A/ja active Pending
- 2017-09-13 US US15/703,753 patent/US10337005B2/en not_active Expired - Fee Related
-
2018
- 2018-03-22 HK HK18103977.1A patent/HK1244509A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521626A5 (cg-RX-API-DMAC7.html) | ||
| Winkle et al. | Noncoding RNA therapeutics—challenges and potential solutions | |
| JP6208228B2 (ja) | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 | |
| Dai et al. | Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers | |
| CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
| EP2948551B1 (en) | Composition comprising an encapsulated antagomir | |
| JP2015525081A5 (cg-RX-API-DMAC7.html) | ||
| JP2010529847A (ja) | 標的ｒｎａ活性の調節のためのオリゴヌクレオチド | |
| JP2013514372A5 (cg-RX-API-DMAC7.html) | ||
| MX2014015641A (es) | Inhibidores de la familia mir-15 de micro-arns. | |
| CN105765069A (zh) | 肝癌相关的基因特异性siRNA、包含所述siRNA的双链寡RNA分子和包含它们的用于预防或治疗癌症的组合物 | |
| Najmuddin et al. | The linkage between microRNA and cancer and its delivery as cancer therapy: a mini-review | |
| KR101861738B1 (ko) | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 | |
| KR101993894B1 (ko) | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 | |
| Szenthe et al. | MicroRNAs as targets and tools in B-cell lymphoma therapy | |
| Gulei et al. | MicroRNas: beating cancer with new powerful weapons | |
| Van Roosbroeck | MicroRNA-specific Argonaute 2 Protein Inhibitors and AGO Loading Inhibitors | |
| Ling et al. | MicroRNAs as Drugs and Drug Targets in Cancer | |
| Aigner et al. | Therapeutic Modulation of MicroRNAs | |
| HK1259394A1 (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |